| Dr. Paul T. Finger | |
|---|---|
| Born | November 26th, 1955 New York, NY |
| Education | Tulane University, Tulane University School of Medicine |
| Years active | 23 |
| Known for | Inventing new treatments, EYECANCERBIG |
| Profession | Ophthalmologist |
| Institutions | New York Eye and Ear Infirmary, NYU School of Medicine |
| Specialism | Oncology (Cancer) |
| Research | Melanomas, Macular Degeneration |
| Notable prizes | America's Best Doctors 2008 |
Paul T. Finger, MD, FACS, is an ophthalmologist in New York, New York specializing in ocular oncology.[1] Dr. Finger has pioneered the use of palladium-103 plaque radiation to treat choroidal melanoma and 3D and high-frequency ultrasound to image intraocular tumors.[2]
Contents |
Dr. Finger received his medical doctorate from Tulane Medical School in 1982. He completed his residency at Manhattan Eye, Ear and Throat Hospital, and his fellowship in ocular oncology at North Shore Hospital in Manhasset, New York.[3]
He is now a Clinical Professor of Ophthalmology at NYU School of Medicine.[3]
Dr. Finger is certified by the American Board of Ophthalmology and is a Fellow of both the American College of Surgeons and the American Academy of Ophthalmology and treats patients from around the world.[2]
His research has focused on melanoma of the choroid, ciliary body and iris. He has written extensively about new ways to detect and treat retinoblastoma, conjunctival melanoma,[4] squamous carcinoma, metastatic cancer to the eye and orbital tumors.[5]
He has helped produce multiple medical textbooks on age-related macular degeneration and eye cancer.[6]
Under the slogan, "Think of sunglasses as sunblock for your eyes," Dr. Finger has campaigned on television to increase the use of sunglasses in order to prevent eye cancers before they happen.[7]
Dr. Finger is spearheading a project by the American Joint Committee on Cancer and the International Union Against Cancer to create a common terminology and set of standards to pool treatment data from eye cancer specialists around the world. This promises to bring major breakthroughs in evaluating competing treatment regimes, and allow doctors to more easily communicate their research to one another.[8]